Skip to main content Help with accessibility Skip to main navigation

Semaglutide (Wegovy)

Indication

Managing overweight and obesity (NICE TA875)

NICE TA 875 - Semaglutide for managing overweight and obesity

Red

Brand:

Wegovy

Nice TA:

875

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

1.1 Semaglutide is recommended as an option for weight management, including weight loss and weight maintenance, alongside a reducedcalorie diet and increased physical activity in adults, only if:

• it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and

• they have at least 1 weight-related comorbidity and:

- a body mass index (BMI) of at least 35.0 kg/m2 , or

- a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet the criteria for referral to specialist weight management services in NICE's guideline on obesity: identification, assessment and management.

Use lower BMI thresholds (usually reduced by 2.5 kg/m2 ) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 27 - Apr - 2023